Author:
Cano Amanda,Ettcheto Miren,Espina Marta,López-Machado Ana,Cajal Yolanda,Rabanal Francesc,Sánchez-López Elena,Camins Antonio,García Maria Luisa,Souto Eliana B.
Abstract
Abstract
Infectious diseases kill over 17 million people a year, among which bacterial infections stand out. From all the bacterial infections, tuberculosis, diarrhoea, meningitis, pneumonia, sexual transmission diseases and nosocomial infections are the most severe bacterial infections, which affect millions of people worldwide. Moreover, the indiscriminate use of antibiotic drugs in the last decades has triggered an increasing multiple resistance towards these drugs, which represent a serious global socioeconomic and public health risk. It is estimated that 33,000 and 35,000 people die yearly in Europe and the United States, respectively, as a direct result of antimicrobial resistance. For all these reasons, there is an emerging need to find novel alternatives to overcome these issues and reduced the morbidity and mortality associated to bacterial infectious diseases. In that sense, nanotechnological approaches, especially smart polymeric nanoparticles, has wrought a revolution in this field, providing an innovative therapeutic alternative able to improve the limitations encountered in available treatments and capable to be effective by theirselves. In this review, we examine the current status of most dangerous human infections, together with an in-depth discussion of the role of nanomedicine to overcome the current disadvantages, and specifically the most recent and innovative studies involving polymeric nanoparticles against most common bacterial infections of the human body.
Funder
Fundació la Marató de TV3
Ministerio de Economía, Industria y Competitividad, Gobierno de España
Publisher
Springer Science and Business Media LLC
Subject
Pharmaceutical Science,Applied Microbiology and Biotechnology,Biomedical Engineering,Molecular Medicine,Medicine (miscellaneous),Bioengineering
Reference122 articles.
1. World Health Organization (WHO). Global health estimates 2016: disease burden by cause, age, sex, by country and by region, 2000–2016 [Internet]. 2018.
https://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html
. Accessed 28 Oct 2020.
2. Rappuoli R, Bloom DE, Black S. Deploy vaccines to fight superbugs. Nature. 2017;552:163–7.
3. Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE, et al. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea : the Global Burden of Disease Study 1990–2016. Lancet Infect Dis. 2018;18:1229–40.
4. GBD. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries : a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018a;18:1211–28.
5. GBD. Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018b;17:1061–782.
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献